AssetMark’s Structure Therapeutics GPCR Stock Holding History
Bought
Maintained
Sold
Other funds holding GPCR
SL
AssetMark's GPCR Position: Q3 2026 in Review
AssetMark increased its Structure Therapeutics (GPCR) stake by 20% in Q3 2026, buying an estimated $25K and bringing the position to 3,259 shares worth $102K. The position accounts for ﹤0.01% of the portfolio, ranked #1650.
AssetMark first reported a position in GPCR in Q2 2024 and has held it in 10 quarters since. The position peaked at $146K in Q2 2026. 118 funds tracked by Wall St. Rank hold GPCR as of Q3 2026.
- AssetMark held 3,259 shares of Structure Therapeutics worth $102K as of Q3 2026.
- AssetMark bought 533 Structure Therapeutics shares in Q3 2026, an estimated $25K.
- Structure Therapeutics made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #1650 holding.
- AssetMark first reported a position in Structure Therapeutics in Q2 2024 and has held it in 10 quarters since.
- AssetMark's Structure Therapeutics position peaked at $146K in Q2 2026.
- 118 funds tracked by Wall St. Rank held Structure Therapeutics as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.